O OVT tests AstraZeneca vaccine with suspicious efficiency

The AstraZeneca/Oxford vaccine, with which Great Britain was the first to vaccinate its mass population in December, has been approved by several other countries and the European Union.

But some governments have decided to recommend it only for people under 65 and even 55 years of age because there was not enough data on its effectiveness for the elderly.

On Sunday, South Africa cancelled the start of its vaccine campaign with a million doses of AstraZeneca vaccine, planned for these days, following a study that revealed its effectiveness “limited to” against the inner strain of the virus.

The first results of this study show that vaccine is only 22 percent effective against the easiest forms of South Africa. There are still no results on its effectiveness against the most severe forms.

“It's too early to remove this vaccine, which is an important part of the global response to the current pandemic”, said Richard Hatchett, head of the CPPI, the Covax mechanism research department set up by O AV to ensure an equal distribution of anti vehicles CO VID-19.

The most important thing is to make the best use of the tools we have,” he said at a press conference in Geneva.

“We think, however, that our vaccine will protect from the most severe forms of the disease,” said an AstraZeneca spokesman.

With average efficiency currently 70 percent, AstraZeneca / Oxford vaccine is currently less efficient than Pfizer/ B NTech, or Modernna, which is more than 90 percent effective.

But this vaccine uses classical technology, which makes it cheaper and easier to save because it can be stored in refrigerators than in a very low temperature, and that is why it is more suitable for mass vaccination campaigns.